Evidentic GmbH

08/08/2022

We know that having access to commercial drugs for early drug development can be difficult, expensive and time-consuming. That's where Evidentic comes in: we repackage commercial medicines into drug aliquots as research consumables. Just let us know which licenced medicine you need and we will take care of everything for you. Visit www.evidentic.com to find out more.

05/08/2022

Therapeutic Enfortumab Vedotin is now available. We repackage licensed medicines into drug aliquots to be used as research consumables. Check this and other at www.evidentic.com.

03/08/2022

Clinical-grade or research-grade molecules? That is the question.
There are significant differences between molecules available on the market, which sometimes are not identifiable at first glance. Let us show you what to consider! https://lnkd.in/d7HDFzA6

01/08/2022

Therapeutic Polatuzumab Vedotin, aliquoted from the commercial drug Polivy® is now in stock. Polatuzumab Vedotin is a CD79b-targeted ADC. Order today at https://evidentic.com/therapeutic-molecules/polatuzumab-vedotin-reference-drug/.

29/07/2022

'Two targets, double success.' This is the idea behind the technology. This consists of using two mAbs with different targets that will produce hexamers, activating the complement-dependent cytotoxicity (CDC) only when both MAbs have bound.

https://lnkd.in/dBDsCRN5

Two targets, double success. This is the logic behind a new approach that uses monoclonal antibody pairs to fight cancer.

21/06/2022

Here is a sneak peek at our poster for the AIS Congress. Come by booth #10 to learn how our can support your research program. Looking forward to meeting you next week!

17/06/2022

Meet our team that is going to be in Montpellier AIS Congress in less than 2 weeks' time. Please drop by booth #10 and have a chat with our team members. Happy to meet you soon!

09/06/2022

We are excited to announce that we are going to be -congress on the 28th and 29th of June. Come and meet us at booth #10.

02/05/2022

A memorandum has been signed between , and on founding a centre for translational research in the area of gene and cell therapy. Read more about this exciting project at https://lnkd.in/eiU3ixEX.

Information on the range of services at Charité – Universtätsmedizin Berlin for patients, physicians, students and scientists

20/04/2022

The star of today is the monoclonal antibody . With TNF-α target, this antibody is available to your projects as a research consumable. Visit www.evidentic.com to learn more about clinical-grade molecules for R&D.

08/04/2022

Host cell proteins (HCPs) are unwanted proteins produced by the host organism during the production of biologics. To meet regulatory criteria, biologics developers must verify that HCPs are in the acceptable range, which for most biologic products is between 10-1000 ppm. Read more about HCPs here https://evidentic.com/host-cell-protein-analysis-for-biologics-development/.

Enjoy your readings and happy Friday!

06/04/2022

Are you looking for clinical-grade molecules for your drug development programs? At Evidentic we source therapeutic molecules as aliquots from commercial drugs. We have a portfolio of 50+ molecules. Our latest addition is Trastuzumab Deruxtecan (https://evidentic.com/therapeutic-molecules/enhertu-trastuzumab-deruxtecan-reference-drug/). To find more please visit our website.